Clinical case of an unusual course of coronavirus infection in patient with chronic disseminated pulmonary tuberculosis and human immunodeficiency virus infection

Abstract

Introduction: The coronavirus 2019 (COVID-19) pandemic demonstrated a negative influence on many underlying diseases, their course, and prognosis. A combined course of active tuberculosis, human immunodeficiency virus (HIV) infection, and COVID-19 is a rare case in the routine clinical practice; therefore, it is of scientific and practical interest. In a 41-year-old patient with severe chronic disseminated pulmonary tuberculosis and HIV infection, presence of tuberculosis mycobacteria, resistance to streptomycin and isoniazid, chronic respiratory failure, cachexia, and immunodeficiency, COVID-19 was manifested only by the detection of SARS-Cov-2 virus from the nasopharynx and did not influence the treatment and prognosis of tuberculosis.

Conclusion: The described case of a combination of active tuberculosis with HIV infection and COVID-19 demonstrated that effective treatment of specific tuberculosis process is quite possible.

Keywords

tuberculosis / human immunodeficiency virus / HIV / COVID-19: SARS-Cov-2 / comorbidity / multimorbidity

References

[1] Huang H, Zhang M, Chen C, et al. Clinical characteristics of COVID-19 in patients with preexisting ILD: A retrospective study in a single center in Wuhan, China. Journal of Medical Virology. 2020;92(11):2742–50. doi: 10.1002/jmv.26174

[2] Huang H., Zhang M., Chen C., et al. Clinical characteristics of COVID-19 in patients with preexisting ILD: A retrospective study in a single center in Wuhan, China // Journal of Medical Virology. 2020. Vol. 92, № 11. P. 2742–2750. doi: 10.1002/jmv.26174

[3] Li F, Li W, Farzan M, et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309(5742):1864–8. doi: 10.1126/science.1116480

[4] Li F., Li W., Farzan M., et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor // Science. 2005. Vol. 309, № 5742. P. 1864–1868. doi: 10.1126/science.1116480

[5] Li X, Zhuang J, Rayford H, et al. Attenuation of bleomycin-induced pulmonary fibrosis by intratracheal administration of antisense oligonucleotides against angiotensinogen mRNA. Current Pharmaceutical Design. 200;13(12):1257–68. doi: 10.2174/138161207780618867

[6] Li X., Zhuang J., Rayford H., et al. Attenuation of bleomycin-induced pulmonary fibrosis by intratracheal administration of antisense oligonucleotides against angiotensinogen mRNA // Current Pharmaceutical Design. 2007. Vol. 13, № 12. P. 1257–1268. doi: 10.2174/138161207780618867

[7] Uhal BD, Dang M, Dang V, et al. Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosis. The European Respiratory Journal. 2013;42(1):198–210. doi: 10.1183/09031936.00015612

[8] Uhal B.D., Dang M., Dang V., et al. Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosis // The European Respiratory Journal. 2013. Vol. 42, № 1. P. 198–210. doi: 10.1183/09031936.00015612